These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 3435068)

  • 21. Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.
    Tse W
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):12-7. PubMed ID: 17948614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. When do levodopa motor fluctuations first appear in Parkinson's disease?
    Stocchi F; Jenner P; Obeso JA
    Eur Neurol; 2010; 63(5):257-66. PubMed ID: 20332641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
    Durif F; Deffond D; Eschalier A; Tournilhac M
    Rev Neurol (Paris); 1992; 148(10):610-4. PubMed ID: 1295055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study.
    Kulisevsky J; Pascual-Sedano B; Barbanoj M; Gironell A; Pagonabarraga J; García-Sánchez C
    Mov Disord; 2007 Jan; 22(1):62-7. PubMed ID: 17115388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.
    Nutt JG; Woodward WR; Hammerstad JP; Carter JH; Anderson JL
    N Engl J Med; 1984 Feb; 310(8):483-8. PubMed ID: 6694694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
    Vaamonde J; Luquin MR; Obeso JA
    Mov Disord; 1990; 5(3):260-2. PubMed ID: 2388647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease.
    Sage JI; Mark MH
    Neurology; 1992 Jan; 42(1 Suppl 1):23-8; discussion 57-60. PubMed ID: 1347908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
    Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation.
    Stocchi F; Ruggieri S; Brughitta G; Agnoli A
    J Neural Transm Suppl; 1986; 22():209-18. PubMed ID: 3465872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Various aspects of motor fluctuations and their management in Parkinson's disease.
    Mizuno Y; Kondo T; Mori H
    Neurology; 1994 Jul; 44(7 Suppl 6):S29-34. PubMed ID: 8047258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease.
    Chase TN; Engber TM; Mouradian MM
    Neurology; 1994 Jul; 44(7 Suppl 6):S15-8. PubMed ID: 7519334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics.
    Nutt JG
    Ann Neurol; 1987 Oct; 22(4):535-40. PubMed ID: 3324948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease.
    Baronti F; Mouradian MM; Davis TL; Giuffra M; Brughitta G; Conant KE; Chase TN
    Ann Neurol; 1992 Dec; 32(6):776-81. PubMed ID: 1471868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function.
    O'Sullivan JD; Said CM; Dillon LC; Hoffman M; Hughes AJ
    Mov Disord; 1998 Nov; 13(6):900-6. PubMed ID: 9827613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease.
    Harder S; Baas H
    Clin Pharmacol Ther; 1998 Aug; 64(2):183-91. PubMed ID: 9728899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of levodopa on the habituation of the acoustic-palpebral reflex in Parkinson's disease.
    Rey RD; Garretto NS; Bueri JA; Simonetti DD; Sanz OP; Sica RE
    Electromyogr Clin Neurophysiol; 1996 Sep; 36(6):357-60. PubMed ID: 8891475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.